Effect of MaxEPA in patients with SLE. A double-blind, crossover study.
Seventeen patients with moderately active SLE participated in a double-blind, crossover study on the effect of MaxEPA, using olive oil as the control substance. During the first 3 months, 8/17 on Max EPA but only 2/17 on the control substance clinically and serologically improved (p = 0.05), but at 6 months there was no difference. The beneficial effect (if any) of MaxEPA on the disease was short-lived.
Westberg
G
G
Department of Nephrology, Sahlgrenska Sjukhuset, University of Göteborg, Sweden.
Tarkowski
A
A
D000328:Adult; D002986:Clinical Trials as Topic; D004281:Docosahexaenoic Acids; D004311:Double-Blind Method; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D015525:Fatty Acids, Omega-3 / Q000592:standards / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged
D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; C045153:Maxepa; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid